Investor Presentation Full Year 2017
Investor Presentation
Full year 2017
Novo Nordisk is now the market leader in the USA within
the modern and new-generation insulin segment
Slide 49
-
Novo Nordisk
Modern insulin and new-generation insulin
volume market shares in the USA
Sanofi
Eli Lilly
USA insulin market by segment
Device penetration
Modern Insulin penetration
tMU
Penetration
160
CAGR volume¹: 2.5%
100%
60%
CAGR value¹: 22.7%
140
50%
80%
120
Fast-acting
40%
100
60%
80
30%
Premix
40%
60
20%
40
Long-acting
20%
10%
20
0
0%
0%
Nov
2012
Nov
2017
Nov
2012
1 CAGR for 5-year period
Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 volume and value (DKK) figures
changing
diabetes®
Source: IQVIA (formerly IMS) monthly MAT Nov, 2017 volume figures
40%
36%
24%
Nov
2017
novo nordiskView entire presentation